Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Evista Stories

2014-04-01 08:30:33

- Prasco to market the Authorized Generic of EVISTA® in the United States CINCINNATI, April 1, 2014 /PRNewswire/ -- Prasco Laboratories, announced today it has signed a marketing and distribution agreement with Eli Lilly and Company (NYSE: LLY) to market the Authorized Generic (AG) version of EVISTA(®) (raloxifene hydrochloride tablets), in 60 mg strength in the United States. Prasco will begin shipping the product immediately. The financial terms of the agreement were not...

2011-08-09 07:00:00

INDIANAPOLIS, Aug. 9, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion. The review includes summaries of previously published information; new, previously unpublished observations; and new data on EVISTA use. EVISTA is indicated for the treatment of osteoporosis in postmenopausal women and reduction in risk of...

2011-05-06 08:52:00

BALTIMORE, May 6, 2011 /PRNewswire/ -- Stenting is safe and effective and superior to balloon angioplasty for treatment of venous stenosis in patients with deep vein thrombosis (DVT), according to results from EVISTA-DVT, presented today as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions in Baltimore. EVISTA-DVT focused on patients with blocked veins who had received clot-buster drug therapy (thrombolysis)....

2010-12-14 00:01:39

Results from an ongoing study examining two drugs to prevent breast cancer found that the drug raloxifene (Evista) was as almost effective as the standard drug tamoxifen (Nolvadex) and also produced fewer side effects. Earlier results of the study had shown that raloxifene was as effective as tamoxifen in reducing non-invasive breast cancer in post-menopausal women at high risk of developing the disease. For both drugs, women experienced a 50 percent reduction in breast cancer risk after 4...

2010-06-28 01:57:00

MUNICH, June 28, 2010 /PRNewswire/ -- - 3D Images Provide New Approach to Monitoring Bone Changes Interim data from a prospective Investigator Initiated Trial (IIT) presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA(R) (raloxifene 60mg; once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated for the treatment and prevention of osteoporosis in postmenopausal women, improves bone quality as measured by...

2010-05-05 15:15:00

MORRISTOWN, N.J., May 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride tablet. Watson's raloxifene hydrochloride tablet is a generic version of Eli Lilly's EVISTA®. EVISTA ® is indicated for the treatment and prevention...

2009-09-23 18:12:00

INDIANAPOLIS, Sept. 23 /PRNewswire-FirstCall/ -- The U.S. District Court for the Southern District of Indiana today upheld Eli Lilly and Company's (NYSE: LLY) method-of-use patents on Evista(R) (raloxifene HCl tablets). In the case of Eli Lilly and Company v. Teva Pharmaceuticals Industries Ltd., the court ruled in favor of Lilly on all accounts for these method-of-use patents, including the patent doctrines of obviousness, enablement, and inequitable conduct. These patents provide...

2009-07-22 05:30:00

INDIANAPOLIS, July 22 /PRNewswire-FirstCall/ -- Increased Volume Drives Revenue Growth Despite Unfavorable Foreign Exchange Impact Foreign Exchange Movements Lead to Improved Gross Margin Percent Earnings Rise 20% to $1.06 (reported); 19% EPS Growth to $1.12 (pro forma non-GAAP) Full-Year 2009 Reported EPS Guidance Range Revised to $4.14 to $4.24 per share Pro forma non-GAAP EPS Guidance Range Raised to $4.20 to $4.30 per share Eli Lilly and Company (NYSE: LLY) today announced...

2009-04-22 18:30:00

Lilly Continues to Defend Intellectual Property Rights for Evista INDIANAPOLIS, April 22 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced that the U.S. District Court for the Southern District of Indiana today issued a preliminary injunction to prevent the launch of a generic version of Lilly's medicine Evista(R) (raloxifene HCl tablets) by Teva Pharmaceuticals until the Court renders its final ruling. Teva had indicated it was prepared to launch the generic version...

2009-04-20 05:30:00

INDIANAPOLIS, April 20 /PRNewswire-FirstCall/ -- Q1 Revenue Increases 5% on a Reported Basis, Driven by Higher Volume. Foreign Exchange Rates Lead to Improved Gross Margin Percentage. Company Achieves Operating Leverage by Growing Revenue Faster Than Cost of Sales and Operating Expenses. Earnings Rise 24% (reported) or 36% (pro forma non-GAAP) to $1.20 per share. Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2009. Due to significant...